Results 171 to 180 of about 34,807 (281)

Single‐Cell Transcriptomic Analysis of Tumor Heterogeneity and the Microenvironment in Pseudomyxoma Peritonei

Advanced Science, Volume 13, Issue 58, 19 October 2026.
This study presents a single‐cell atlas of pseudomyxoma peritonei spanning primary and paired metastatic lesions. Distinct epithelial substates, stromal remodeling, immune exclusion, lipid metabolic reprogramming, and a candidate angiogenic network were identified in metastatic lesions.
Xi Li, Lei Wang, Lei Ai, Zimeng Li, Zhaochangci Chen, Yuchen Luo, Tianran Zhang, Mengjia Liao, Songhao Wang, Jiajia Cui, Ke Liu, Chengxian Guo, Guodong Liu, Jiye Yin, Wei Wu   +14 more
wiley   +1 more source

ABCB1 Frameshift Deletion in Skye Terriers With Potential Pharmacogenetic Relevance

Animal Genetics, Volume 57, Issue 5, October 2026.
ABSTRACT Ivermectin‐associated neurotoxicity is a potentially life‐threatening condition caused by disruption of the ABCB1 encoded P‐glycoprotein drug transporter in certain dog breeds. Skye terriers are considered at increased risk of ivermectin toxicity despite the absence of an identified molecular cause.
Monica Nielsen, Hanne Gredal, Åsa Karlsson, Jennifer R. S. Meadows, Maja Arendt   +4 more
wiley   +1 more source

Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3397-3406, October 2026.
Aim In the GENESECT study, no significant gemcitabine (GEM) metabolism‐related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab‐paclitaxel, which has metabolic pathways different from GEM.
Takashi Yokokawa, Daiki Tsuji, Masahiro Hatori, Kazuyoshi Kawakami, Masahiko Nakao, Takuya Yano, Yuichiro Arakawa, Keisuke Matsuo, Yasukata Ohashi, Masato Ozaka, Naoki Sasahira, Yasuhiko Sakata, Yuki Kogure, Shinya Tamaki, Atsushi Wada, Yusuke Taki, Wataru Suzuki, Kazuo Kobayashi, Hiroshi Ishii, Kunihiko Itoh, Masakazu Yamaguchi, Kenichi Suzuki   +21 more
wiley   +1 more source

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3375-3386, October 2026.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen, Mathilde Rønne Koch, Cecilie Utke Rank, Christen Lykkegaard Andersen, Allan Weimann, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Flemming Nielsen, Tore Bjerregaard Stage, Sara Bisgaard Jensen, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff   +14 more
wiley   +1 more source

Advancing Personalized Medicine in Psychiatry: A Descriptive Pilot Study Integrating Pharmacogenetics and Pharmacokinetics in Long-Acting Antipsychotic Treatment. [PDF]

Pharmaceutics
Gil-Rodriguez A, Recarey-Rama S, Vidal-Millares M, Toja-Camba FJ, Tajes M, Prado-Robles V, Durán-Maseda MJ, García MP, Rodríguez-Viyuela A, Sánchez-Fariña P, Abeledo-Lameiro MJ, Páramo M, Facal F, Arrojo Romero M, Diaz Pereira A, Mondelo-García C, Fernández-Ferreiro A, Carracedo A, Maroñas O.   +18 more
europepmc   +1 more source

Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3387-3396, October 2026.
Aims CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted.
Julian Peter Müller, Vladimir N. Belov, Sabrina Yamoune, Bob Miller, Mohammed Hasoumi, Jolanta Tupiec, Thea Laurentius, L. Cornelius Bollheimer, Julia C. Stingl, Katja S. Just   +9 more
wiley   +1 more source

Development and validation of an open data model for pharmacogenetics to enable semantic interoperability in clinical practice. [PDF]

Pharmacogenomics J
Sharma V, McDermott JH, Keen J, Koikkalainen H, McNicoll I, Davies A, Newman WG.   +6 more
europepmc   +1 more source

Pharmacogenetics in Ophthalmology [PDF]

Proceedings of the Royal Society of Medicine, 1971
openaire   +2 more sources

The Association Between CD40 rs1883832 Polymorphism and Cancer Susceptibility: A Systematic Review and Meta‐Analysis

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT The CD40 gene, a key immune regulatory molecule, has been implicated in tumorigenesis, and its functional polymorphism rs1883832 located in the Kozak sequence, may modulate cancer susceptibility by influencing CD40 expression. To clarify inconsistent epidemiological findings, a comprehensive meta‐analysis was conducted to evaluate the ...
Bingxiang Wang, Min Gao, Shuhao Fan, Huaiju Ge, Chao Li, Cheng Li   +5 more
wiley   +1 more source

Next‐Generation Sequencing‐Based Molecular Profiling and Management of Advanced Solid Tumors: A Real‐World Experience in a Community‐Based Academic Cancer Center

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Background Advances in molecular and cell biology have led to a paradigm shift in cancer management. We implemented next‐generation sequencing (NGS) at our community‐based academic cancer center over a decade ago. We sought to optimize the use of genomics and understand its impact in identifying actionable genomic alterations to determine ...
Gayathri Moorthy, Annette Sereika, Karen Kaul, Megan Parilla, Mir B. Alikhan, Michael Bouma, Dyson Wake, Peter J. Hulick, Henry M. Dunnenberger, Linda M. Sabatini, Mathew Yang, Kathy A. Mangold, Erin Proctor, Nicholas Evans, Nicholas Miller, Donald L. Helseth Jr, Darryck Maurer, Justin Brueck, Janardan Khandekar, Bruce Brockstein   +19 more
wiley   +1 more source